secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0000105770-25-000007
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

West Pharma Q4 net sales $748.8M (+2.3%), adj EPS $1.82; FY25 guidance $6.00-$6.20 EPS
--------------------------------------------------------------------------------

- Q4 organic net sales grew 3.3%, driven by Proprietary Products (+4.5%) led by self-injection devices.
- FY 2025 guidance: net sales $2.875B-$2.905B; adjusted EPS $6.00-$6.20 (vs. FY24 $6.75).
- Proprietary Products Q4 HVP sales were 74% of segment; Biologics unit had high-single-digit organic growth.
- FY 2024 free cash flow $276.4M, down 33.3%; $560.9M spent on share repurchases during year.
- CEO cited improving HVP trends in Biologics/Generics and growth from Annex 1 and GLP-1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577025000007/0000105770-25-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577025000007/wst-20250213.htm
  HTML page:      https://secwatch.observer/filing/0000105770-25-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer